| 1 |
NCT02262819 |
Recruiting |
Human Immunity Against Staphylococcus Aureus Skin Infection |
- Staphylococcus Aureus Skin Infection
|
|
Interventional
|
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Evaluate the local in vivo skin immune response to bacteria.
- Evaluate the keratinocyte responses to bacterial challenge.
- Determine if abnormalities in specific immune pathways, such as IL-17 and vitamin D metabolism, are present in subjects with recognized susceptibility to S. aureus infections.
- (and 3 more...)
|
300 |
All |
2 Years to 65 Years (Child, Adult, Older Adult) |
NCT02262819 |
140199
14-I-0199 |
|
October 10, 2014 |
January 1, 2025 |
January 1, 2025 |
October 13, 2014 |
January 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 2 |
NCT03372941 |
Not yet recruiting |
Hospital Avoidance Strategies for ABSSSI |
|
|
Interventional
|
Phase 4 |
- Washington University School of Medicine
- Barnes-Jewish Hospital
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Healthcare utilization related to ABSSSI
- Healthcare cost related to ABSSSI management
- Clinical response
- (and 5 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03372941 |
201709136 |
|
November 1, 2018 |
September 1, 2019 |
December 1, 2019 |
December 14, 2017 |
October 3, 2018 |
|
|
|
| 3 |
NCT03131843 |
Recruiting |
Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination |
|
- Drug: Alcohol
- Drug: No alcohol
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Skin infection
- Skin infection symptoms
- Feasibility of recruitment
- (and 2 more...)
|
170 |
All |
2 Months to 18 Years (Child, Adult) |
NCT03131843 |
33391 |
|
May 1, 2017 |
December 2018 |
December 2018 |
April 27, 2017 |
May 2, 2017 |
|
- Pediatrician Clinic
North York, Ontario, Canada
|
|
| 4 |
NCT03637400 |
Not yet recruiting |
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment |
- Methicillin-resistant Staphylococcus Aureus
- Skin Infection
|
|
Interventional
|
Phase 2 |
- Los Angeles Biomedical Research Institute
- National Institute of Allergy and Infectious Diseases (NIAID)
- Washington University School of Medicine
- University of California, Los Angeles
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical cure at Early Clinical Response (ECR) visit
- Clinical cure at the End of Treatment (EOT) visit
- Clinical cure at the One Month Follow-up (OMFU) visit
- (and 5 more...)
|
462 |
All |
9 Years to 85 Years (Child, Adult, Older Adult) |
NCT03637400 |
30284 |
|
October 16, 2018 |
April 1, 2022 |
November 1, 2022 |
August 20, 2018 |
August 20, 2018 |
|
- Harbor-UCLA Medical Center
Torrance, California, United States - Washington University
Saint Louis, Missouri, United States
|
|
| 5 |
NCT03643952 |
Recruiting |
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) |
- Bacteremia
- Soft Tissue Infections
- Skin Diseases, Infectious
|
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of participants with an Adverse Event
- Percentage of Participants that Discontinued Study Due to an AE
- Percentage of Participants with Clinical Success
- (and 7 more...)
|
20 |
All |
1 Year to 17 Years (Child) |
NCT03643952 |
3009-029
MK-3009-029
184155 |
|
December 6, 2018 |
May 14, 2021 |
May 14, 2021 |
August 23, 2018 |
January 31, 2019 |
|
- Japan Community Health Care Organization Chukyo Hospital ( Site 0030)
Nagoya, Aichi, Japan - Japan Community Health care Organization Kyushu Hospital ( Site 0016)
Kitakyushu, Fukuoka, Japan - Maebashi Red Cross Hospital ( Site 0012)
Maebashi, Gunma, Japan - (and 13 more...)
|
|
| 6 |
NCT02814916 |
Recruiting |
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
- Methicillin-Resistant Staphylococcus Aureus
- Bacterial Infections
- Staphylococcal Skin Infections
|
- Drug: Dalbavancin single dose
- Drug: Dalbavancin two dose
- Drug: Comparator
|
Interventional
|
Phase 3 |
- Durata Therapeutics Inc., an affiliate of Allergan plc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with abnormal audiologic assessment
- Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora
- Clinical response
- (and 11 more...)
|
300 |
All |
3 Months to 17 Years (Child) |
NCT02814916 |
DUR001-306
2014-005281-30 |
|
March 30, 2017 |
January 25, 2019 |
January 25, 2019 |
June 28, 2016 |
June 7, 2018 |
|
- University of South Alabama
Mobile, Alabama, United States - Maricopa Integrated Health System
Phoenix, Arizona, United States - Southbay Pharma Research
Buena Park, California, United States - (and 40 more...)
|
|
| 7 |
NCT02566928 |
Recruiting |
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence |
- Methicillin-Resistant Staphylococcus Aureus
- Recurrence
- Staphylococcal Skin Infections
- Antibiotic Resistance
|
- Drug: 2% mupirocin ointment
- Other: Chlorhexidine wash
- Behavioral: Hygiene protocol
|
Interventional
|
Phase 4 |
- Clinical Directors Network
- Rockefeller University
- Patient-Centered Outcomes Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- SSTI Recurrence Rate
- Clinical Response Questionnaire
- Subsequent SSTI Self-Report
- (and 9 more...)
|
278 |
All |
7 Years to 70 Years (Child, Adult, Older Adult) |
NCT02566928 |
CER-1402-10800 |
CAMP-2 |
October 2015 |
November 2018 |
December 31, 2018 |
October 2, 2015 |
July 21, 2017 |
|
- NYU Lutheran Family Health Centers
Brooklyn, New York, United States - NYU Lutheran Medical Center Emergency Department
Brooklyn, New York, United States - Coney Island Hospital
Brooklyn, New York, United States - (and 3 more...)
|
|
| 8 |
NCT03178747 |
Recruiting |
Tzanck Smear With Methylene Blue Stain for Herpes |
- Herpes Simplex
- Herpes Zoster
- Varicella Zoster
|
- Diagnostic Test: Methylene blue
- Diagnostic Test: Giemsa stain
|
Interventional
|
Phase 3 |
- Chulalongkorn University
- Dermatological Society of Thailand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Sensitivity
- Factors that contribute the results from Methylene blue staining
- Specificity
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03178747 |
674/59 |
|
March 7, 2017 |
December 7, 2017 |
March 6, 2018 |
June 7, 2017 |
August 4, 2017 |
|
- Division of Dermatology, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
|
|
| 9 |
NCT03747497 |
Recruiting |
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection |
- Skin Diseases, Bacterial
- Gram-Positive Bacterial Infections
|
- Drug: contezolid acefosamil
- Drug: linezolid 600 mg
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Early clinical response in the ITT population
- Incidence of treatment-emergent adverse events (safety and tolerability)
- Early clinical response in the mITT and micro-ITT population
- (and 3 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03747497 |
MRX4-201 |
|
November 15, 2018 |
May 30, 2019 |
June 30, 2019 |
November 20, 2018 |
February 15, 2019 |
|
- eStudy Site
Chula Vista, California, United States - Long Beach Clinical Trials
Long Beach, California, United States - St Joseph's Medical Associates
Stockton, California, United States - (and 3 more...)
|
|
| 10 |
NCT02582177 |
Not yet recruiting |
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis |
|
- Drug: Ketoconazole + betamethasone dipropionate
- Drug: Clotrimazole + Dexamethasone acetate
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage change in the total score of signs and symptoms
- Mycological cure (Negative result for the direct mycological examination)
- Participants satisfaction regarding the treatment
|
160 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02582177 |
ACH-CND-03(05/15) |
DaVinci |
August 1, 2018 |
January 1, 2019 |
February 1, 2019 |
October 21, 2015 |
April 9, 2018 |
|
|
|
| 11 |
NCT03487549 |
Recruiting |
Cantharidin and Occlusion in Verruca Epithelium |
- Common Wart
- Warts Hand
- Warts
- (and 9 more...)
|
- Drug: VP-102-cantharidin topical film forming solution
- Device: VP-102 Applicator
|
Interventional
|
Phase 2 |
- Verrica Pharmaceuticals Inc.
- Instat Consulting, Inc.
- Paidion Research, Inc.
- BioClinica, Inc.
|
Industry / Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cohort 1-Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).
- Cohort 2-Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new) at the EOT Visit (Day 84).
- Cohort 1-Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84).
- (and 5 more...)
|
55 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT03487549 |
VP-102-105 |
COVE-1 |
March 27, 2018 |
May 3, 2019 |
July 5, 2019 |
April 4, 2018 |
December 21, 2018 |
|
- Cohort 2: Applied Research Center of Arkansas
Little Rock, Arkansas, United States - Cohort 2: Solutions Through Advanced Research
Jacksonville, Florida, United States - Cohort 2: The Indiana Clinical Trials Center
Plainfield, Indiana, United States - (and 2 more...)
|
|
| 12 |
NCT03059992 |
Recruiting |
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases |
- Invasive Candidiases
- Mucocutaneous Candidiasis
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of Global Response
- Assessment of Recurrence of Baseline Fungal Infection
- Assessment of survival
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03059992 |
SCY-078-301
2017-000381-29 |
FURI |
April 1, 2017 |
September 2019 |
December 2019 |
February 23, 2017 |
February 15, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - UC Davis Medical Center
Sacramento, California, United States - Emory University Hospital Midtown
Atlanta, Georgia, United States - (and 27 more...)
|
|
| 13 |
NCT02629419 |
Recruiting |
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis |
- Candidiasis, Chronic Mucocutaneous
|
|
Interventional
|
Phase 2 |
- Matinas BioPharma Nanotechnologies, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Symptoms of mucocutaneous candidiasis
- Area under the plasma concentration versus time curve (AUC)
- Peak Plasma Concentration (Cmax)
- Adverse events, changes in laboratory parameters
|
16 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02629419 |
MB-70004
16-I-0002 |
CAMB |
September 2016 |
September 2019 |
December 2019 |
December 14, 2015 |
January 8, 2019 |
|
- National Institute of Allergy and Infectious Disease (NIAID)
Bethesda, Maryland, United States
|
|
| 14 |
NCT03731169 |
Recruiting |
CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels |
- Aspergillosis Invasive
- Fungal Infection
|
- Genetic: Voriconazole genotype-specific dosing
- Drug: Standard of Care
|
Interventional
|
Phase 4 |
- University Health Network, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Voriconazole trough concentrations at steady-state
- Number of dose adjustments
- Genotype-specific dosages
- Genotype-specific dosing on treatment success/failure
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03731169 |
15-9226 |
|
January 10, 2018 |
June 2019 |
June 2019 |
November 6, 2018 |
November 6, 2018 |
|
- Toronto General Hospital
Toronto, Ontario, Canada - Princess Margaret Cancer Care Centre
Toronto, Ontario, Canada
|
|
| 15 |
NCT03717623 |
Not yet recruiting |
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants |
- Posaconazole
- Pharmacokinetics
- Invasive Candidiases
- (and 4 more...)
|
- Drug: Posaconazole pharmacokinetics
|
Interventional
|
Phase 4 |
- Melbourne Health
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pre-dose plasma Posaconazole concentrations
- Clinical symptoms affecting plasma Posaconazole concentrations.
- The number/proportion of patients achieving desirable pre-dose plasma Posaconazole concentrations.
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03717623 |
2017.105 |
POPULAR |
March 2019 |
June 30, 2020 |
December 31, 2020 |
October 24, 2018 |
January 28, 2019 |
|
|
|
| 16 |
NCT03578679 |
Recruiting |
Treatment of Pediculosis (Head Lice) in Senegal |
|
- Drug: Ivermectin Oral Product
|
Interventional
|
Not Applicable |
- Institut de Recherche pour le Developpement
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Parasiticidal efficacy: disappearance of head lice (zero lice) on day 7
|
450 |
Female |
6 Years and older (Child, Adult, Older Adult) |
NCT03578679 |
SEN17/16 |
IVERAZITH |
July 11, 2018 |
September 16, 2018 |
December 30, 2018 |
July 6, 2018 |
August 8, 2018 |
|
- Institut de Recherche pour le Developpement
Dakar, Senegal
|
|
| 17 |
NCT01782131 |
Recruiting |
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) |
|
- Drug: Posaconazole
- Drug: Voriconazole
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Who Died by Week 6
- Number of Participants Achieving Global Clinical Response at Week 12
- Number of Participants Who Died by Week 12
- (and 3 more...)
|
600 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT01782131 |
P06200
2011-003938-14
5592-069 |
|
September 25, 2013 |
June 19, 2019 |
September 16, 2019 |
February 1, 2013 |
November 26, 2018 |
|
- Call for Information (Investigational Site 0010)
Birmingham, Alabama, United States - Call for Information (Investigational Site 0127)
Chicago, Illinois, United States - Call for Information (Investigational Site 0250)
Boston, Massachusetts, United States - (and 27 more...)
|
|
| 18 |
NCT01386437 |
Recruiting |
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections |
- Chronic Mucocutaneous Candidiasis
- Invasive Aspergillosis
- CARD9
- APECED
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Immunological mechanisms of fungal susceptibility
- Determine immunological profile of mucosal fungal infections
- Determine microbiologic test usefullness
|
700 |
All |
Child, Adult, Older Adult |
NCT01386437 |
110187
11-I-0187 |
|
June 30, 2011 |
|
|
July 1, 2011 |
February 8, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 19 |
NCT03846635 |
Recruiting
New |
Handheld Infrared Thermometer to Evaluate Cellulitis |
- Cellulitis
- Cellulitis of Arm
- Cellulitis of Leg
|
|
Observational
|
|
- McGill University Health Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Difference in skin temperature between affected and contra-lateral limb
- Change in Skin Temperature
- Change in Maximal Dimensions of Cellulitis
- Clinical symptoms of cellulitis as measured by the patient global impression of change scale
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03846635 |
2019-4850 |
HI-TEC |
August 28, 2018 |
August 27, 2019 |
August 27, 2019 |
February 19, 2019 |
February 19, 2019 |
|
- McGill University Health Centre
Montreal, Quebec, Canada - Jewish General Hospital
Montreal, Quebec, Canada
|
|
| 20 |
NCT03785834 |
Recruiting |
The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis |
- Cellulitis
- Pseudocellulitis
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Length of hospitalization
- Decreased antibiotic use over the course of the hospitalizations
- Number of Participants with a decrease rate of readmission
|
60 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03785834 |
2018H0147 |
|
May 25, 2018 |
June 1, 2019 |
June 1, 2019 |
December 24, 2018 |
December 24, 2018 |
|
- The Ohio State University Dermatology
Gahanna, Ohio, United States
|
|
| 21 |
NCT03556917 |
Recruiting |
The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy. |
|
- Combination Product: iontophoresis + caffeine
|
Interventional
|
Phase 2
Phase 3 |
- Universidade Norte do Paraná
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- thickness
- temperature
- score quality of life
|
30 |
Female |
20 Years to 40 Years (Adult) |
NCT03556917 |
2.264.773 |
|
June 14, 2018 |
December 17, 2018 |
February 4, 2019 |
June 14, 2018 |
October 5, 2018 |
|
- Rodrigo Antonio Carvalho Andraus
Londrina, Paraná, Brazil
|
|
| 22 |
NCT03474523 |
Recruiting |
Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment |
|
- Other: Experimental group
- Other: Control group
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Decrease in perimeter measures
- Changes in body mass index
- Changes in weight
- (and 2 more...)
|
40 |
Female |
18 Years to 40 Years (Adult) |
NCT03474523 |
Fisioterapia Bahía |
|
October 20, 2017 |
May 22, 2018 |
June 28, 2018 |
March 22, 2018 |
May 3, 2018 |
|
- Faculty of Nursing and Physiotherapy. University of Cadiz
Cádiz, Spain
|
|
| 23 |
NCT03814343 |
Recruiting
New |
Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis |
- Fungal Infection
- Onychomycosis
- Fungus, Nail
|
- Drug: amphotericin B in 30% DMSO
- Drug: 30% DMSO
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Effectiveness of amphotericin B in 30% DMSO solution comparing with 30% DMSO solution in NDMs onychomycosis treatment
- Median time to mycological cure of patients with amphotericin B in 30% DMSO solution comparing with 30% DMSO solution in NDMs onychomycosis treatment
- Clinical cure of amphotericin B in 30% DMSO solution comparing with 30% DMSO solution in NDMs onychomycosis treatment
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03814343 |
799/2018 |
amphotericin |
January 15, 2019 |
January 15, 2020 |
June 15, 2020 |
January 24, 2019 |
January 29, 2019 |
|
- Department of Dermatology Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
|
|
| 24 |
NCT03837431 |
Not yet recruiting
New |
Cutaneous Leishmaniasis Diagnostic Study |
|
- Diagnostic Test: Skin slit
- Diagnostic Test: Dental broach
- Diagnostic Test: Tape disc
|
Observational
|
|
- Institute of Tropical Medicine, Belgium
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Sensitivity, specificity of CL detect Rapid Test using skin slit sampling
- Sensitivity, specificity of CL detect Rapid Test using dental broach sampling
- Sensitivity, specificity of CL detect Rapid Test with skin slit or dental broach sampling
- (and 6 more...)
|
350 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT03837431 |
1219/18 |
|
February 15, 2019 |
February 1, 2020 |
May 1, 2020 |
February 12, 2019 |
February 12, 2019 |
|
- Leishmania Research and Treatment Center, University of Gondar hospital
Gondar, Ethiopia
|
|
| 25 |
NCT03829917 |
Not yet recruiting
New |
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis |
- Cutaneous Leishmaniasis, American
|
- Drug: Miltefosine and Paromomycin
- Drug: miltefosine
- Drug: paromomycin
|
Interventional
|
Phase 2
Phase 3 |
- Fundacion Nacional de Dermatologia
- Hospital Dermatológico de Jorochito
- Ministerio de Salud de Bolivia, Programa Nacional de Leishmaniasis
- Alfred Berman Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Size of cutaneous ulcers
|
120 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT03829917 |
AB-2018-02 |
|
February 2019 |
February 1, 2020 |
July 31, 2020 |
February 4, 2019 |
February 4, 2019 |
|
|
|
| 26 |
NCT03816176 |
Not yet recruiting
New |
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants |
- Invasive Mucormycosis
- Invasive Aspergillosis
|
- Drug: Isavuconazonium sulfate
|
Interventional
|
Phase 2 |
- Astellas Pharma Global Development, Inc.
- Astellas Pharma Inc
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety assessed by Adverse Events (AEs)
- Number of participants with vital sign abnormalities and /or adverse events
- Safety assessed by 12- lead electrocardiogram (ECG)
- (and 17 more...)
|
30 |
All |
1 Year to 17 Years (Child) |
NCT03816176 |
9766-CL-0107 |
|
February 2019 |
August 2021 |
August 2021 |
January 25, 2019 |
January 25, 2019 |
|
|
|
| 27 |
NCT03784248 |
Not yet recruiting |
Mediterranean Visceral Leishmaniasis With Leishmania Infantum |
|
- Other: blood donation and isolation of leuco-platelet layers
|
Observational
|
|
- Centre Hospitalier Universitaire de Nice
|
Other |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- genetic level characterization of the isolates of L. infantum
|
1400 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03784248 |
17-API-02 |
AsymptoGen |
January 15, 2019 |
January 15, 2021 |
August 15, 2022 |
December 21, 2018 |
December 21, 2018 |
|
- Nice Hospital
Nice, France
|
|
| 28 |
NCT03762070 |
Recruiting |
Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru |
|
- Device: CL Detect™ Rapid Test
|
Observational
|
|
- Naval Medical Research Center
|
U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- The performance (sensitivity and specificity) of the CL Detect™ Rapid Test
- Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test when scraping is used to obtain tissue samples.
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03762070 |
LRDD-PERU-02 |
|
October 2, 2018 |
March 2019 |
April 2019 |
December 3, 2018 |
December 3, 2018 |
|
- Universidad Peruana Cayetano Heredia (UPCH)
Lima, Peru - U.S. Naval Medical Research Center Unit No. 6 (NAMRU-6)
Puerto Maldonado, Peru
|
|
| 29 |
NCT03646981 |
Not yet recruiting |
Evaluation of Antibody Detection Tests for Visceral Leishmaniasis Diagnosis in Eastern Africa |
|
- Device: Leishmania Ab Rapid Test (CTK, Biotech)
|
Observational
|
|
- Foundation for Innovative New Diagnostics, Switzerland
- University of Gondar
- Kenya Medical Research Institute
- (and 5 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- RDT performance
- Time to diagnosis
- New diagnostic algorithm
|
1684 |
All |
4 Years to 100 Years (Child, Adult, Older Adult) |
NCT03646981 |
P08002-VL-DX-EAFR |
VL-DX-EAFR |
November 2018 |
July 2019 |
December 2019 |
August 24, 2018 |
August 24, 2018 |
|
|
|
| 30 |
NCT03636659 |
Recruiting |
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition |
|
- Drug: Amphotericin B Liposome
- Drug: AmBisome (Amphotericin B) Liposome
|
Interventional
|
Phase 1 |
- Aurobindo Pharma Ltd
- Axis Clinicals Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimation of Cmax-ss, Maximum concentration over the steady state dosing interval
- Estimation of AUC0-tau, Area under the plasma concentration time curve over the steady state dosing interval
- Evaluation of Cmin-ss
- (and 5 more...)
|
140 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03636659 |
CR179-17
CTRI/2018/04/013350 |
|
May 2, 2018 |
March 2019 |
March 2019 |
August 17, 2018 |
August 17, 2018 |
|
- International Centre for Diarrhoeal Disease Research b
Dhaka, Bangladesh - Kala-Azar medical Research Centre
Muzaffarpur, Bihar, India - Rajendra Memorial Research Institute of Medical Sciences
Patna, Bihar, India
|
|
| 31 |
NCT03399955 |
Recruiting |
Short Course Regimens for Treatment of PKDL (Sudan) |
- PKDL - Post-Kala-Azar Dermal Leishmanioid
|
- Drug: Paromomycin
- Drug: Ambisome
- Drug: Miltefosine
|
Interventional
|
Phase 2 |
- Drugs for Neglected Diseases
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Definitive Cure
- Incidence of treatment-emergent adverse events
- Pharmacokinetics of Miltefosine
- (and 4 more...)
|
110 |
All |
6 Years to 60 Years (Child, Adult) |
NCT03399955 |
DNDi-MILT COMB-02-PKDL |
|
May 9, 2018 |
May 9, 2021 |
May 1, 2022 |
January 17, 2018 |
July 19, 2018 |
|
- Prof. Elhassan Centre for tropical Medicine
Doka, Gedaref, Sudan
|
|
| 32 |
NCT03349931 |
Recruiting |
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis |
- Invasive Aspergillosis in Patients With Onco-haematological Diseases
|
- Diagnostic Test: DNA extraction and detection of Aspergillus fumigatus in serum samples
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
- Société ADEMTECH SA
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Performance of PCR for Aspergillosis diagnosis
- Detection of azole resistance
|
420 |
All |
18 Years and older (Adult, Older Adult) |
NCT03349931 |
K-170102
2017-A01518-45 |
MYCOGENIE |
February 5, 2018 |
April 2019 |
April 2019 |
November 22, 2017 |
May 1, 2018 |
|
- CHU Bordeaux, Groupe hospitalier
Bordeaux, France - CHU de DIJON, Hôpital du bocage
Dijon, France - CHRU de Lille, Hôpital Claude Huriez
Lille, France - (and 3 more...)
|
|
| 33 |
NCT03336372 |
Recruiting |
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients |
|
|
Interventional
|
Early Phase 1 |
- Center for Clinical Studies, Texas
- LEO Pharma
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete clearance at Week 4
- Partial clearance at Week 4
- Percentage of subjects who sustain complete clearance of MCs in the treatment area at Week 24
- Percentage of subjects who clear MCs outside of the treatment area at Week 24
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03336372 |
IIS-Picato-1386 |
|
December 20, 2017 |
July 1, 2018 |
December 15, 2018 |
November 8, 2017 |
January 26, 2018 |
|
- Center for Clinical Studies
Houston, Texas, United States
|
|
| 34 |
NCT03303898 |
Recruiting |
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - |
|
- Procedure: Blood sampling
|
Interventional
|
Not Applicable |
- Centre Hospitalier Universitaire de Nice
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- immune response of lymphocytes from asymptomatic carriers
|
30 |
All |
19 Years and older (Adult, Older Adult) |
NCT03303898 |
17-AOI-04 |
Asymptoleish |
November 10, 2017 |
November 10, 2017 |
March 10, 2019 |
October 6, 2017 |
July 24, 2018 |
|
- Nice Hospital
Nice, France
|
|
| 35 |
NCT03292835 |
Not yet recruiting |
Complex Cutaneous Leishmaniasis Healing Study in Algeria |
|
|
Observational
|
|
- K. W. Stahl
- Institut Pasteur
- University of Erlangen-Nürnberg Medical School
- Waisenmedizin e. V. Promoting Access to Essential Medicine
|
Other / Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Lesion Epithelisation
- No healing progress with LeiClean
|
100 |
All |
up to 90 Years (Child, Adult, Older Adult) |
NCT03292835 |
ALG 17/003 |
LeiClean |
September 1, 2019 |
March 30, 2020 |
March 31, 2020 |
September 26, 2017 |
December 24, 2018 |
|
|
|
| 36 |
NCT03221075 |
Recruiting |
Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy |
|
|
Observational
|
|
- University Hospital of Cologne
- Radboud University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Treatment response to antifungal therapy in patients with an invasive Aspergillosis caused by an azole resistant pathogen.
- Overall survival
|
220 |
All |
Child, Adult, Older Adult |
NCT03221075 |
17-024 |
CLARITY |
March 1, 2017 |
June 1, 2020 |
July 1, 2020 |
July 18, 2017 |
October 30, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany - Radboud University Nijmegen Medical Center
Nijmegen, Netherlands
|
|
| 37 |
NCT03129646 |
Recruiting |
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
|
- Drug: Miltefosine
- Drug: Paromomycin
- Drug: Sodium stibogluconate
|
Interventional
|
Phase 3 |
- Drugs for Neglected Diseases
- The Netherlands Cancer Institute
- The Institute of Endemic Diseases (IEND), University of Khartoum
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Definitive Cure
- Incidence of Treatment-Emergent Adverse Events
- Efficacy
- (and 3 more...)
|
576 |
All |
4 Years to 50 Years (Child, Adult) |
NCT03129646 |
DNDi-MILT/PM-01-VL |
|
January 24, 2018 |
November 30, 2019 |
November 30, 2019 |
April 26, 2017 |
January 15, 2019 |
|
- Abdurafi MSF Health Center
Ābderafī, Amhara, Ethiopia - University Hospital of Gondar
Gondar, Ethiopia - Kacheliba Hospital
Kacheliba, West Pokot, Kenya - (and 4 more...)
|
|
| 38 |
NCT03073967 |
Recruiting |
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults |
|
- Drug: Pritelivir
- Drug: Foscarnet
|
Interventional
|
Phase 2 |
- AiCuris Anti-infective Cures GmbH
- Medpace, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy measured by time to lesion healing
- Efficacy measured by average pain score
- Efficacy measured by pain rate
- (and 19 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03073967 |
AIC316-03-II-01 |
PRIOH-1 |
May 8, 2017 |
August 2019 |
October 2019 |
March 8, 2017 |
February 5, 2019 |
|
- Yale University School of Medicine - Infectious Diseases
New Haven, Connecticut, United States - Geogetown University Hospital
Washington, District of Columbia, United States - Midway Immunology and Research Center (MIRC)
Fort Pierce, Florida, United States - (and 15 more...)
|
|
| 39 |
NCT03023111 |
Not yet recruiting |
Miltefosine and GM-CSF in Cutaneous Leishmaniasis |
|
- Drug: Sbv
- Drug: Miltefosine plus placebo
- Drug: Miltefosine plus GM-CSF
|
Interventional
|
Phase 3 |
- Hospital Universitário Professor Edgard Santos
- Oswaldo Cruz Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Final cure rate or complete cicatrization of the ulcer
- Initial cure rate or initial cicatrization of the ulcer
- Healing time
- Clinical and laboratory adverse events
|
300 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03023111 |
Mil GM CL-2017 |
|
March 2017 |
March 2019 |
September 2019 |
January 18, 2017 |
January 20, 2017 |
|
|
|
| 40 |
NCT03013673 |
Recruiting |
Predicting Visceral Leishmaniasis in HIV Infected Patients |
|
|
Observational
|
|
- Institute of Tropical Medicine, Belgium
- University of Gondar, Gondar, Ethiopia
- Medecins Sans Frontieres, Netherlands
- Bureau of Health, Abdurafi, Ethiopia
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of asymptomatic Leishmania infection
- Incidence rate of asymptomatic Leishmania infection
- Evolution of Leishmania infection markers
- (and 7 more...)
|
1045 |
All |
18 Years and older (Adult, Older Adult) |
NCT03013673 |
ITM0915 |
PreLeisH |
October 11, 2017 |
October 2021 |
December 2021 |
January 6, 2017 |
October 11, 2018 |
|
- Abdurafi Health Center
Abderafi, Amhara, Ethiopia
|
|
| 41 |
NCT03004092 |
Recruiting |
Novel Biomarkers for Invasive Aspergillosis |
|
|
Interventional
|
Not Applicable |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy of serum bmGT
- Diagnostic accuracy of a combination of serum bmGT and serum GM
- Prognostic value of serum bmGT
- (and 5 more...)
|
226 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03004092 |
S59863 |
|
January 2017 |
December 2019 |
February 2020 |
December 28, 2016 |
May 3, 2018 |
|
- University Hospitals Leuven
Leuven, Belgium
|
|
| 42 |
NCT02912026 |
Not yet recruiting |
Radiolabelled IV and Oral Metabolism Study of F901318 |
|
- Drug: IV F901318
- Drug: Oral F901318
|
Interventional
|
Phase 1 |
- F2G Ltd.
- Quotient Clinical
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
10 |
Male |
40 Years to 65 Years (Adult, Older Adult) |
NCT02912026 |
F901318-01-08-16 |
ADME |
May 2019 |
July 2019 |
July 2019 |
September 23, 2016 |
August 1, 2018 |
|
- Quotient Clinical
Nottingham, Nottinghamshire, United Kingdom
|
|
| 43 |
NCT02841215 |
Not yet recruiting |
Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies |
- Gale
- Severe Forms of Scabies
- Oral Parasitic Drug
- Ivermectin
|
- Drug: Ivermectin 200 µg/kg
- Drug: Ivermectin 400 µg/kg
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Rate of a successful treatment defined by : -Two negative parasitologic or two dermoscopic exams
- Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions
- Rate of adverse effects
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT02841215 |
P140939 |
GALECRUSTED |
March 2017 |
March 2019 |
March 2019 |
July 22, 2016 |
December 8, 2016 |
|
- Henri Mondor Hospital
Creteil, France
|
|
| 44 |
NCT02656797 |
Recruiting |
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis |
|
- Drug: Topical Amphotericin-B 0.4% liposomal gel
|
Interventional
|
Phase 2 |
- Soroka University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Complete re-epithelization
- Lesion size
- Skin manifestations
- Evidence of lesihmania infection
|
108 |
All |
18 Years and older (Adult, Older Adult) |
NCT02656797 |
sor017715ctil |
|
January 30, 2018 |
January 2020 |
January 2021 |
January 15, 2016 |
April 20, 2018 |
|
- Soroka University Medical Center
Beer Sheva, Israel
|
|
| 45 |
NCT02429505 |
Recruiting |
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry |
|
|
Observational
|
|
- Knight Therapeutics (USA) Inc
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- number of patients cured
- number of patients with adverse effects
|
25 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02429505 |
IMP 2127-4 |
|
July 2015 |
March 2020 |
March 2021 |
April 29, 2015 |
March 7, 2018 |
|
- Fast Track
North Potomac, Maryland, United States
|
|
| 46 |
NCT02427308 |
Recruiting |
Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry |
- Leishmaniasis or Other Uses of Miltefosine
|
|
Observational
|
|
- Knight Therapeutics (USA) Inc
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- number of patients with adverse effects during pregnancy
- number of patients with adverse pregnancy outcome
- number of patients with adverse fetal outcome
|
2 |
Female |
Child, Adult, Older Adult |
NCT02427308 |
IMP 2127-1 |
|
July 2015 |
March 2025 |
March 2026 |
April 28, 2015 |
March 7, 2018 |
|
- Fast Track
North Potomac, Maryland, United States
|
|
| 47 |
NCT02193022 |
Recruiting |
Miltefosine for Children With PKDL |
- Post Kala Azar Dermal Leishmaniasis
|
|
Interventional
|
Phase 3 |
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Thrasher Research Fund
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1. Safety of 12 weeks treatment with Miltefosine at allometric dose in children ages < 18 years old.
- 2. Cure rate of 12 weeks treatment with Miltefosine at allometric dose in children ages < 18 years old.
|
80 |
All |
730 Days to 6569 Days (Child) |
NCT02193022 |
PR-13045 |
|
July 2014 |
June 2019 |
June 2019 |
July 17, 2014 |
November 27, 2018 |
|
- International Centre for Diarrheal Disease Research, Bangladesh
Dhaka, Bangladesh
|
|
| 48 |
NCT01878383 |
Recruiting |
Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture |
|
|
Observational
|
|
- University of Alabama at Birmingham
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sensitivity of detection of HSV DNA by GeneXpert PCR from specimens obtained from the genital tract of pregnant women in active labor or of non-pregnant women in STI clinics, as compared with routine PCR detection of viral DNA (pregnant and nonpregnant
- HSV disease among neonates delivered to women without active genital HSV lesions Specificity, positive predictive value, and negative predictive value of detection of HSV DNA by GeneXpert PCR from specimens obtained from the genital tract of pregnant
|
12700 |
Female |
19 Years and older (Adult, Older Adult) |
NCT01878383 |
DMID 11-0070 |
|
January 2014 |
September 2019 |
September 2019 |
June 14, 2013 |
February 8, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - University of Colorado at Denver Health Sciences Center
Aurora, Colorado, United States - (and 12 more...)
|
|
| 49 |
NCT01641796 |
Available |
Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis |
|
|
Expanded Access
|
|
- U.S. Army Medical Research and Materiel Command
|
U.S. Fed |
|
|
|
All |
Child, Adult, Older Adult |
NCT01641796 |
S-12-13
S-12-13/M-10337 |
|
|
|
|
July 17, 2012 |
August 15, 2018 |
|
- Walter Reed National Military Medical Center
Bethesda, Maryland, United States - Military Treatment Facilities
Multiple Locations, Maryland, United States
|
|
| 50 |
NCT01277796 |
Available |
Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis |
|
- Device: Heat pack conduction-heat therapy
|
Expanded Access
|
|
- Universidad Peruana Cayetano Heredia
- Tulane University School of Medicine
|
Other |
|
|
|
All |
8 Years to 80 Years (Child, Adult, Older Adult) |
NCT01277796 |
032-08 |
HECT |
|
|
|
January 17, 2011 |
January 17, 2011 |
|
|
|
| 51 |
NCT00508963 |
Available |
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis |
- Leishmaniasis, Cutaneous
- Leishmaniasis, Mucocutaneous
|
- Drug: sodium stibogluconate (Pentostam)
|
Expanded Access
|
|
- University of California, San Francisco
|
Other |
|
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00508963 |
UCSF Infectious Diseases |
|
|
|
|
July 30, 2007 |
December 15, 2014 |
|
- University of CA at San Francisco Hospitals and Clinics
San Francisco, California, United States
|
|
| 52 |
NCT00344188 |
Recruiting |
Diagnosis and Treatment of Leishmanial Infections |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
200 |
All |
2 Years to 80 Years (Child, Adult, Older Adult) |
NCT00344188 |
010238
01-I-0238 |
|
August 22, 2001 |
|
|
June 26, 2006 |
February 4, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 53 |
NCT03619746 |
Recruiting |
Point-of-Care Ultrasound Educational Initiative for Insect Bites |
- Cellulitis
- Insect Bites
- Insect Stings
|
- Behavioral: POCUS Educational Intervention
|
Interventional
|
Not Applicable |
- Albert Einstein College of Medicine
- Jacobi Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
304 |
All |
3 Months to 20 Years (Child, Adult) |
NCT03619746 |
2018-9176 |
USED4BUGBITE |
August 10, 2018 |
August 2020 |
August 2020 |
August 8, 2018 |
September 17, 2018 |
|
- Jacobi Medical Center
Bronx, New York, United States
|
|
| 54 |
NCT03312946 |
Recruiting |
Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite. |
- Body Fat Distribution
- Cellulitis
|
|
Interventional
|
Not Applicable |
- Indústria Brasileira Equipamentos Médicos - IBRAMED
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improve body contour
- Improve appearance of cellulite
|
30 |
Female |
18 Years to 60 Years (Adult) |
NCT03312946 |
Ibramedmodellata |
|
October 13, 2017 |
December 4, 2017 |
February 4, 2018 |
October 18, 2017 |
October 18, 2017 |
|
- Ibramed - Indústria Brasileira de Equipamentos Médicos
Amparo, São Paulo, Brazil
|
|
| 55 |
NCT02715037 |
Not yet recruiting |
Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis |
- Acute Tonsillitis
- Peritonsillar Cellulitis
- Infectious Mononucleosis
|
|
Observational
|
|
- Tejs Ehlers Klug
- Statens Serum Institut
- Aarhus University Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Prevalence of Fusobacterium necrophorum in throat swab cultures
- Number of participants with recurrent throat infections (questionnaire)
- Number of participants without eradication of throat pathogens (throat cultures)
- (and 2 more...)
|
350 |
All |
15 Years to 40 Years (Child, Adult) |
NCT02715037 |
52683 |
|
June 2016 |
May 2019 |
December 2021 |
March 22, 2016 |
March 22, 2016 |
|
- Aarhus University Hospital
Aarhus, Denmark
|
|
| 56 |
NCT03676686 |
Not yet recruiting |
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients with cured or improved fungal infection
- Tolerability to the device used
- Other clinical signs and symptoms
- Dermatology Quality of life
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03676686 |
Nåva Foot Cream_1 |
|
September 2018 |
March 2019 |
March 2019 |
September 19, 2018 |
September 20, 2018 |
|
|
|
| 57 |
NCT03320486 |
Recruiting |
Non-inferiority Trial of Dapaconazole Versus Ketoconazole |
|
- Drug: Dapaconazole
- Drug: Ketoconazole
|
Interventional
|
Phase 3 |
- Biolab Sanus Farmaceutica
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of participants with therapeutic cure
- Proportion of participants maintaining therapeutic cure
- Number of days until clinical cure
- Number of adverse events per participant
|
360 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03320486 |
GDN 018/16 |
|
November 1, 2017 |
November 2019 |
November 2019 |
October 25, 2017 |
January 16, 2019 |
|
- Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
Campinas, SP, Brazil
|
|
| 58 |
NCT02882438 |
Recruiting |
Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis |
- Foot Infection Tinea Pedis
|
- Drug: infected group
- Drug: control group
|
Interventional
|
Phase 1 |
- Ahmed A. H. Abdellatif
- Al-Azhar University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Assessment the antifungal activity of Ginkgo Biloba & Glucosamine
- Stability test for different dosage forms
|
30 |
All |
20 Years to 40 Years (Adult) |
NCT02882438 |
AlAzharGGATP |
|
January 2016 |
September 2019 |
October 2019 |
August 29, 2016 |
November 14, 2018 |
|
- Assiut Clinic
Assiut, Egypt
|
|
| 59 |
NCT03280927 |
Recruiting |
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis |
- Mild to Moderate Onychomycosis Due to Dermatophyte
|
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Completely cured subjects
- Complete or almost complete cure rates
- Mycologic cure rates
- Clinical efficacy rates
|
100 |
All |
19 Years and older (Adult, Older Adult) |
NCT03280927 |
JBL_OM_IV |
|
November 10, 2017 |
August 31, 2019 |
October 1, 2019 |
September 13, 2017 |
June 4, 2018 |
|
- Konkuk University Medical Center
Seoul, Korea, Republic of
|
|
| 60 |
NCT03171584 |
Not yet recruiting |
Antifungal Drugs in Treatment of Onychomycosis |
- Antifungal Drugs in Onychomycosis
|
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
60 |
All |
20 Years to 60 Years (Adult) |
NCT03171584 |
oncho |
|
July 1, 2017 |
June 1, 2019 |
November 1, 2019 |
May 31, 2017 |
May 31, 2017 |
|
|
|
| 61 |
NCT03066336 |
Recruiting |
A Study to See if Low Level Laser Light Can Help to Treat Toenail Fungus |
|
- Device: Erchonia LunulaLaser
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent (%) of toenails attaining mycologic cure at study endpoint
|
54 |
All |
18 Years and older (Adult, Older Adult) |
NCT03066336 |
EC_LL_MYC_PS |
|
April 10, 2017 |
June 2018 |
June 2018 |
February 28, 2017 |
January 18, 2018 |
|
- University Of Miami Department of Dermatology
Miami, Florida, United States
|
|
| 62 |
NCT03022903 |
Recruiting |
Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis |
- Toenail Onychomycosis
- Distal and Lateral Subungual Toenail Onychomycosis
|
- Procedure: Aminolevulinic Acid (ALA)
|
Interventional
|
Not Applicable |
- University of Alabama at Birmingham
- DUSA Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects diagnosed with presence of subungual culture after 3rd treatment session
- Number of subjects with clinical cure based on photographs after the 3rd treatment session
- Compare rates of mycological and clinical cure after three treatments between two groups with different ALA incubation times
- (and 2 more...)
|
10 |
Female |
19 Years to 70 Years (Adult, Older Adult) |
NCT03022903 |
F150128007 |
|
September 2015 |
September 2019 |
September 2019 |
January 18, 2017 |
October 22, 2018 |
|
- Dermatology at the Whitaker Clinic
Birmingham, Alabama, United States
|
|
| 63 |
NCT02961634 |
Not yet recruiting |
Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis |
|
- Device: Nailner 2 in 1
- Drug: Ciclopirox 8%
|
Interventional
|
Phase 3 |
- MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA
- Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Percent of improvement of mycosis by reducing the area of the lesion that will be measured at times D1 and D90
- Presence of fungal structures in nail affected by onychomycosis in visits 1 and final through mycological examination
- Number of patients reporting reduction in discomfort caused by onychomycosis through a subjective evaluation questionnaire
- Number of adverse events reported and related to the product investigational
|
46 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02961634 |
EN16-0467-01 |
|
April 2017 |
August 2017 |
August 2017 |
November 11, 2016 |
March 31, 2017 |
|
|
|
| 64 |
NCT02812043 |
Recruiting |
Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis |
- Non-dermatophyte Onychomycosis
|
- Device: 1,064nm Long-pulsed Nd:YAG
- Drug: Amorolfine
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mycological cure rate in patients with onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment
- number of participants who develop paronychia after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment
- pain score in participants who received long-pulsed Nd:YAG and the adjunct treatment
- Depth of nail involvement of onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02812043 |
391/2558(EC1) |
|
August 2016 |
August 2018 |
August 2018 |
June 23, 2016 |
September 6, 2017 |
|
- Department of Dermatology Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
|
|
| 65 |
NCT02724384 |
Recruiting |
Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis |
|
- Device: MOE Plasma Delivery System A
- Device: MOE Plasma Delivery System B
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0
- Efficacy as assessed by Clinical, Mycological and Complete Cure Rates assessed in accordance with FDA Guidance for onychomycosis trials issued March 7, 2016
|
75 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02724384 |
OM-0030 |
|
March 2016 |
December 2018 |
February 2019 |
March 31, 2016 |
September 14, 2017 |
|
- MOE Medical Devices Site 5
Quincy, Massachusetts, United States - MOE Medical Devices Site 4
Philadelphia, Pennsylvania, United States - MOE Medical Devices Investigational Site 3
Pittsburgh, Pennsylvania, United States - (and 4 more...)
|
|
| 66 |
NCT02644551 |
Recruiting |
The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis |
|
- Drug: CELEXT07
- Drug: Penlac
- Other: vehicle solution
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 52 Weeks
- Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 52 Weeks.
- Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 52 Weeks.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT02644551 |
CELEXT07-01 |
|
November 2016 |
May 2018 |
September 2018 |
January 1, 2016 |
April 26, 2017 |
|
- Clinique podiatrique de Montréal
Montreal, Quebec, Canada
|
|
| 67 |
NCT03471455 |
Not yet recruiting |
Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis |
|
- Drug: Isotretinoin
- Drug: Terbinafine
- Drug: Itraconazole 200 mg
|
Interventional
|
Phase 2 |
- Postgraduate Institute of Medical Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03471455 |
INT/IEC/2017/850 |
ISORD |
April 2018 |
January 2019 |
January 2019 |
March 20, 2018 |
May 1, 2018 |
|
|
|
| 68 |
NCT02922686 |
Not yet recruiting |
Penicillin for the Emergency Department Outpatient Treatment of CELLulitis |
- Cellulitis
- Wound Infection
- Abscess
|
- Drug: Flucloxacillin
- Drug: Phenoxymethylpenicillin
- Drug: Placebo (for phenoxymethylpenicillin)
|
Interventional
|
Phase 4 |
- Royal College of Surgeons, Ireland
- Health Research Board, Ireland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Investigator-determined clinical response
- Early Clinical Response (ECR)
- Clinical Treatment Failure
- (and 6 more...)
|
414 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT02922686 |
EudraCT Number: 2016-001528-69
HRB HRA Project ID |
PEDOCELL |
December 2016 |
December 2019 |
December 2019 |
October 4, 2016 |
October 4, 2016 |
|
- Department of Emergency Medicine, Connolly Hospital,
Blanchardstown, Dublin, Ireland - Department of Emergency Medicine, Mercy University Cork
Cork, Greenville Place, Ireland - Department of Emergency Medicine, Cork University Hospital
Cork, Wilton, Ireland - (and 2 more...)
|
|
| 69 |
NCT03827798 |
Not yet recruiting
New |
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa |
|
- Drug: CFZ533
- Drug: Placebo to CFZ533
- Drug: LYS006
- Drug: Placebo to LYS006
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hidradenitis Suppurativa Clinical Response (HiSCR)
|
90 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03827798 |
CCFZ533H12201BC |
|
February 14, 2019 |
June 17, 2020 |
April 28, 2021 |
February 1, 2019 |
February 15, 2019 |
|
|
|
| 70 |
NCT03827694 |
Recruiting
New |
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections |
- Pulmonary Invasive Mold Infections
- Pulmonary Invasive Aspergillosis
|
- Diagnostic Test: Non-Invasive Testing for PIMI
|
Observational
|
|
- Duke University
- Children's Hospital of Philadelphia
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Likelihood ratio of the galactomannan assay to return a positive result among subjects determined to have PIMI
- Likelihood ratio of galactomannan assay to return a negative result among subjects determined not to have PIMI
- Likelihood ratio of fungal PCRs (Aspergillus PCR, Mucorales PCR) to return a positive result among subjects determined to have PIMI
- (and 6 more...)
|
400 |
All |
120 Days to 21 Years (Child, Adult) |
NCT03827694 |
Pro00094558
R01AI139032 |
DOMINIC |
October 30, 2018 |
December 31, 2022 |
December 31, 2022 |
February 1, 2019 |
February 6, 2019 |
|
- Emory University
Atlanta, Georgia, United States - Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States - University of Chicago Medicine, Comer Children's
Chicago, Illinois, United States - (and 8 more...)
|
|
| 71 |
NCT03784313 |
Not yet recruiting |
Perforator Flaps for Axillary Hidradenitis Suppurativa |
- Axillary Hidradenitis Suppurativa
|
- Procedure: skin repair by axillary perforator flaps
- Procedure: skin repair by secondary wound healing
|
Interventional
|
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- To compare the efficacy at 6 months on the healing time of perforators flaps and secondary intention wound healing after wide surgical excision, for axillary HS stage II or III insufficiently responsive to conventional systemic treatment.
- Recurrence rate during the 12-months follow-up defined as: new signs of disease in the axilla despite surgical treatment and Hurley staging of the involved axilla
- Shoulder mobility on the operated side, evaluated by the DASH score
- (and 12 more...)
|
88 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03784313 |
P170931J
2018-A01244-51 |
HS-PAX |
February 2019 |
July 2021 |
January 2022 |
December 21, 2018 |
December 21, 2018 |
|
- Service PREMIER ( Plastique, Reconstruction, Esthétique, Microchirugie et Régénération tissulaire)CHU TENON- APHP
Paris, France
|
|
| 72 |
NCT03713632 |
Not yet recruiting |
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
- Drug: Secukinumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR)
- Proportion of patients with HS flares
- Participants achieving NRS30
|
471 |
All |
18 Years and older (Adult, Older Adult) |
NCT03713632 |
CAIN457M2302 |
SUNRISE |
February 1, 2019 |
June 18, 2021 |
April 22, 2022 |
October 22, 2018 |
October 22, 2018 |
|
|
|
| 73 |
NCT03713619 |
Not yet recruiting |
This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). |
|
- Drug: secukinumab
- Drug: placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR)
- proportion of patients with HS flares
- Participants achieving NRS30
|
471 |
All |
18 Years and older (Adult, Older Adult) |
NCT03713619 |
CAIN457M2301 |
SUNSHINE |
February 1, 2019 |
June 18, 2021 |
April 22, 2022 |
October 22, 2018 |
October 22, 2018 |
|
|
|
| 74 |
NCT03672292 |
Recruiting |
Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis |
- Invasive Pulmonary Aspergillosis
|
- Drug: SCY-078
- Drug: Voriconazole
- Other: Oral Placebo Tablets
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Adverse events; discontinuation due to AE; death
- Composite clinical, radiological and mycological response (global response)
- Death
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03672292 |
SCY-078-206
2018-002565-18 |
SCYNERGIA |
January 22, 2019 |
September 2020 |
October 2020 |
September 14, 2018 |
February 15, 2019 |
|
- Memorial Hermann Hospital Texas Medical Center Clinical Research Unit
Houston, Texas, United States
|
|
| 75 |
NCT03656081 |
Not yet recruiting |
Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole |
- Chronic Pulmonary Aspergillosis
|
- Drug: inhaled Ambisome®
- Drug: inhaled placebo
- Drug: Itraconazole
|
Interventional
|
Phase 3 |
- Poitiers University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Composite efficacy criterion defined by the association of clinical improvement/stability and radiological improvement evaluated at 6 months
- major events during follow-up period
- relapse
- mycological response
|
224 |
All |
18 Years and older (Adult, Older Adult) |
NCT03656081 |
CPAAARI |
|
November 2018 |
May 2021 |
May 2023 |
September 3, 2018 |
September 3, 2018 |
|
|
|
| 76 |
NCT03643185 |
Recruiting |
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis |
|
|
Observational
|
|
- Shanghai Pulmonary Hospital, Shanghai, China
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cytokines levels
- Exacerbation
- High attenuation mucus (HAM)
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03643185 |
20180627 |
|
December 2014 |
December 2018 |
April 2019 |
August 22, 2018 |
August 27, 2018 |
|
- Shanghai Pulmonary Hospital
Shanghai, Shanghai, China
|
|
| 77 |
NCT03628924 |
Recruiting |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
- Drug: Guselkumab dose 1
- Drug: Guselkumab dose 2
- Drug: Guselkumab dose 3
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
- Change From Baseline in Participant's Total Abscess and Inflammatory Nodule (AN) Count at Week 16
- Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
- (and 16 more...)
|
180 |
All |
18 Years and older (Adult, Older Adult) |
NCT03628924 |
CR108500
2018-001176-38
CNTO1959HDS2001 |
NOVA |
September 4, 2018 |
August 10, 2020 |
October 29, 2020 |
August 14, 2018 |
January 28, 2019 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - UC Davis School of Medicine
Sacramento, California, United States - Olympian Clinical Research
Largo, Florida, United States - (and 45 more...)
|
|
| 78 |
NCT03607487 |
Recruiting |
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa |
|
- Drug: INCB054707
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of treatment-emergent adverse events (TEAEs)
- Apparent oral clearance of INCB054707
- Apparent oral volume of distribution of INCB054707
- (and 9 more...)
|
36 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03607487 |
INCB 54707-203 |
|
September 18, 2018 |
November 2019 |
May 2020 |
July 31, 2018 |
January 4, 2019 |
|
- Wiseman Dermatology Research
Winnipeg, Manitoba, Canada - Brunswick Dermatology Center
Fredericton, New Brunswick, Canada - SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, Canada - (and 11 more...)
|
|
| 79 |
NCT03569371 |
Recruiting |
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of treatment-emergent adverse events (TEAEs)
- Apparent oral clearance of INCB054707
- Apparent oral volume of distribution of INCB054707
- (and 13 more...)
|
10 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03569371 |
INCB 54707-202 |
|
June 11, 2018 |
April 2019 |
April 2019 |
June 26, 2018 |
December 6, 2018 |
|
- Dermatology Research Associates
Los Angeles, California, United States - Forward Clinical Trials, Inc.
Tampa, Florida, United States - Rockefeller University
New York, New York, United States - Penn State Hershey Dermatology
Hershey, Pennsylvania, United States
|
|
| 80 |
NCT03512275 |
Recruiting |
A Study of Bermekimab in Patients With Hidradenitis Suppurativa |
|
- Drug: Bermekimab Monoclonal Antibody 400 mg
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Dose Limiting Toxicity [Safety and Tolerability]
- Hidradenitis Suppurativa Clinical Response (HiSCR)
- Pharmacokinetics (PK)
- (and 8 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03512275 |
2018-PT045 |
|
June 20, 2018 |
December 2018 |
December 2018 |
April 30, 2018 |
August 31, 2018 |
|
- Tennessee Clinical Research Center
Nashville, Tennessee, United States
|
|
| 81 |
NCT03469232 |
Recruiting |
Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome |
- Intense-exuberant Stomach Fire Syndrom
- Acute Pericoronitis
- Recurrent Aphthous Stomatitis
- Recurrent Herpes Simplex Labialis
|
- Drug: Huanglian-Jiedu Decoction
|
Interventional
|
Phase 1
Phase 2 |
- China Academy of Chinese Medical Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in the Intense-Exuberant Stomach Fire Syndrome scores
- Change from baseline of each symptom in Intense-Exuberant Stomach Fire Syndrome scores
- The proportion of patients whose Intense-Exuberant Stomach Fire Syndrome were disappeared
- (and 11 more...)
|
240 |
All |
18 Years to 60 Years (Adult) |
NCT03469232 |
HLJD-V3 |
|
April 4, 2018 |
September 1, 2018 |
November 1, 2018 |
March 19, 2018 |
April 10, 2018 |
|
- Third affiliated hospital of Beijing University of traditional Chinese medicine
Beijing, Beijing, China - Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine
Beijing, Beijing, China - Affiliated Hospital to Chengdu University of traditional Chinese medicine
Chengdu, Sichuan, China
|
|
| 82 |
NCT03443336 |
Recruiting |
Azole-resistance in Aspergillus |
|
|
Observational
|
|
- University Hospital, Basel, Switzerland
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Azole-resistance in Aspergillus (A.) fumigatus
|
400 |
All |
Child, Adult, Older Adult |
NCT03443336 |
2017-00984 |
me17Khanna |
June 1, 2017 |
December 31, 2018 |
December 31, 2019 |
February 23, 2018 |
March 1, 2018 |
|
- Division of Infectious Diseases and Hospital Epidemiology
Basel, Switzerland
|
|
| 83 |
NCT03327727 |
Recruiting |
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults |
- Invasive Aspergillosis
- Invasive Pulmonary Aspergillosis
|
- Drug: Investigational Agent: VL-2397
- Drug: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause mortality (ACM)
- ACM
- Number of participants with adverse events
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03327727 |
VL2397-201
2017-003435-11 |
|
February 20, 2018 |
December 31, 2019 |
December 31, 2019 |
October 31, 2017 |
February 6, 2019 |
|
- University of Alabama at Birmingham Hospital, Division of Infectious Diseases
Birmingham, Alabama, United States - UC San Diego Moores Cancer Center
La Jolla, California, United States - UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases
Sacramento, California, United States - (and 24 more...)
|
|
| 84 |
NCT03289585 |
Recruiting |
A National Registry For Patients With Hidradenitis Suppurativa |
|
|
Observational
|
|
- Montefiore Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Skin-related quality of life
- Presence and severity of depression
- Skin-related of life
- (and 8 more...)
|
400 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03289585 |
2014-3835 SRC |
|
August 2015 |
August 2020 |
August 2020 |
September 21, 2017 |
February 7, 2019 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 85 |
NCT03288337 |
Recruiting |
Impact of Hidradenitis Suppurativa on Quality of Life Functions |
- Hidradenitis Suppurativa
- Quality of Life
|
|
Observational
|
|
- Montefiore Medical Center
- AbbVie
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Dermatology-related quality of life
- Presence and severity of depression
- Subject-reported subject health
- (and 7 more...)
|
400 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03288337 |
2014-3873 |
|
April 2015 |
August 2020 |
August 2020 |
September 20, 2017 |
February 8, 2019 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 86 |
NCT03275870 |
Recruiting |
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa |
- Hidradenitis Suppurativa
- Hidradenitis
- Acne Inversa
- (and 3 more...)
|
|
Interventional
|
Phase 1
Phase 2 |
- Elena Gonzalez Brant, MD
- University of Pittsburgh
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in disease severity
- Improvement in quality of life
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03275870 |
PRO17030612 |
|
September 28, 2017 |
June 2019 |
June 2019 |
September 8, 2017 |
October 19, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 87 |
NCT03267394 |
Not yet recruiting |
Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis |
- Thymus and Activation Regulated Chemokine
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- thymus and activation regulated chemokine (TARC) in diagnosis of Allergic bronchopulmonary aspergellosis
|
75 |
All |
Child, Adult, Older Adult |
NCT03267394 |
TARC in diagnosis of ABPA |
|
October 2017 |
October 2018 |
November 2018 |
August 30, 2017 |
August 30, 2017 |
|
|
|
| 88 |
NCT03265366 |
Not yet recruiting |
Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses |
- Allergic Bronchopulmonary Aspergilloses
|
- Device: MRI
- Device: CT scan (standard reference)
|
Interventional
|
Not Applicable |
- University Hospital, Bordeaux
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions)
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT03265366 |
CHUBX 2016/12 |
ABPA-MR |
September 2017 |
September 2018 |
September 2018 |
August 29, 2017 |
August 30, 2017 |
|
- CHU de Bordeaux
Pessac, France
|
|
| 89 |
NCT03221621 |
Recruiting |
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS |
|
- Procedure: Wide Excision
- Drug: Adalimumab Injection
|
Interventional
|
Phase 4 |
- Erasmus Medical Center
- Sanquin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cost-utility
- Clinical efficacy using HiSCR
- Clinical efficacy using change in HS-PGA
- (and 25 more...)
|
128 |
All |
18 Years and older (Adult, Older Adult) |
NCT03221621 |
HS-COST |
HS-COST |
July 31, 2018 |
July 31, 2022 |
July 31, 2022 |
July 18, 2017 |
February 8, 2019 |
|
- Erasmus MC
Rotterdam, Netherlands
|
|
| 90 |
NCT03217474 |
Recruiting |
Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis |
|
- Procedure: FLDEB
- Drug: Ganciclovir (GCV)
- Device: Femtosecond laser
|
Interventional
|
Not Applicable |
- Chunxiao Wang
- Sun Yat-sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Healing time
- Corneal re-epithelization
- Corneal opacity and vascularization
- (and 4 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03217474 |
2017KYPJ052 |
|
July 20, 2017 |
December 30, 2018 |
December 30, 2019 |
July 14, 2017 |
February 22, 2018 |
|
- Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity
Guangzhou, Guangdong, China
|
|
| 91 |
NCT03203122 |
Recruiting |
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa |
- Hidradenitis Suppurativa
- Acne Inversa
|
- Other: IPL laser
- Other: No sham treatment
|
Interventional
|
Not Applicable |
- Zealand University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HiScore
- Sartorius score
- Physician global assesment
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03203122 |
REG-115-2016 |
|
August 7, 2017 |
August 1, 2018 |
August 1, 2019 |
June 29, 2017 |
June 29, 2017 |
|
- University hospital Zealland
Roskilde, Denmark
|
|
| 92 |
NCT03199781 |
Recruiting |
Motorized Mechanical Massage Associated With Cosmetics in Improving Body Contour and Appearance of Gynoid Lipodystrophy |
|
- Device: Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics
|
Interventional
|
Not Applicable |
- Indústria Brasileira Equipamentos Médicos - IBRAMED
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Anthropometric evaluation
- Evaluation of the degree of cellulite
- Assessment of adipose tissue thickness
- Assessment of skin elasticity
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03199781 |
Ibramed |
|
May 30, 2017 |
August 20, 2017 |
September 15, 2017 |
June 27, 2017 |
June 27, 2017 |
|
- Ibramed - Indústria Brasileira de Equipamentos Médicos
Amparo, São Paulo, Brazil
|
|
| 93 |
NCT03146676 |
Recruiting |
The Ohio State University Dermatology Biorepository, Molecular Biology and Genetics of Hidradenitis Suppurativa |
|
|
Observational
|
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders
|
175 |
All |
Child, Adult, Older Adult |
NCT03146676 |
2010H0331 |
|
April 19, 2017 |
January 2018 |
January 2022 |
May 10, 2017 |
June 1, 2017 |
|
- OSU Dermatology East
Gahanna, Ohio, United States
|
|
| 94 |
NCT03121235 |
Recruiting |
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome. |
- Aspergillosis, Invasive Pulmonary
|
- Diagnostic Test: PCR based detection of azole resistance in A. fumigatus
|
Observational
|
|
- Erasmus Medical Center
- Gilead Sciences
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of antifungal treatment failure
- Demonstrate that early detection of azole resistance reduces the overall mortality.
- Demonstrate that a step down to oral posaconazole is a reasonable treatment option in patients that have responded to at least 2 weeks of IV antifungal therapy.
- Comparison of antifungal treatment failure in patients with the presence of RAM.
|
280 |
All |
18 Years and older (Adult, Older Adult) |
NCT03121235 |
MEC-2016-664 |
AzorMan |
April 20, 2017 |
October 15, 2019 |
October 15, 2019 |
April 20, 2017 |
March 22, 2018 |
|
- Academisch Medisch Centrum
Amsterdam, Netherlands - VU Medisch Centrum
Amsterdam, Netherlands - Universitair Medisch Centrum Groningen
Groningen, Netherlands - (and 5 more...)
|
|
| 95 |
NCT03099980 |
Recruiting |
Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa |
|
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hidradenitis Suppurativa Clinical Response (HiSCR)
|
21 |
All |
18 Years and older (Adult, Older Adult) |
NCT03099980 |
CAIN457AUS03T |
|
July 11, 2016 |
August 2018 |
January 2019 |
April 4, 2017 |
March 15, 2018 |
|
- Tufts Medical Center, Department of Dermatology
Boston, Massachusetts, United States
|
|
| 96 |
NCT03084952 |
Not yet recruiting |
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients |
- Leishmaniasis; American, Cutaneous
- Drug Side Effect
|
- Drug: 18-Methoxycoronaridine
- Drug: Glucantime
|
Interventional
|
Phase 2 |
- Infan Industria Quimica Farmaceutica Nacional
- Evandro Chagas National Institute of Infectious Disease
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lesion Reduction and Re-epithelization - Definitive Cure
- Lesion Reduction and Re-epithelization - Partial Cure
- Clinical Failure
|
52 |
All |
18 Years to 59 Years (Adult) |
NCT03084952 |
HB/F2-002/2016 |
|
November 2018 |
March 2019 |
November 2019 |
March 21, 2017 |
August 9, 2018 |
|
- Instituto Evandro Chagas
Ananindeua, PA, Brazil
|
|
| 97 |
NCT03846648 |
Not yet recruiting
New |
CyPep-1 in Cutaneous Warts |
|
|
Interventional
|
Phase 1 |
- Centre for Human Drug Research, Netherlands
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in heart rate
- Changes in blood pressure (systolic and diastolic)
- Changes in body temperature
- (and 3 more...)
|
58 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03846648 |
CHDR1803
NL67664.056.18 |
|
March 11, 2019 |
February 28, 2020 |
February 28, 2020 |
February 19, 2019 |
February 19, 2019 |
|
|
|
| 98 |
NCT03830047 |
Not yet recruiting
New |
Effect of Laser in Treatment of Vulval Warts |
|
|
Interventional
|
Not Applicable |
- Aljazeera Hospital
- National Research Center, Egypt
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The number of women who will be completely cured by laser beam
|
40 |
Female |
18 Years to 40 Years (Adult) |
NCT03830047 |
laser |
|
February 7, 2019 |
October 15, 2019 |
November 20, 2019 |
February 5, 2019 |
February 5, 2019 |
|
- Algazeerah and Kasralainy hospital
Giza, Egypt
|
|
| 99 |
NCT03828773 |
Recruiting
New |
PTX3-targeted Antifungal Prophylaxis |
- Candidiasis
- Fungal Infection
- Acute Myeloid Leukemia
- (and 2 more...)
|
- Drug: Posaconazole
- Drug: Fluconazole
|
Interventional
|
Not Applicable |
- Bochud Pierre-Yves
- Swiss National Science Foundation
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Cumulative incidence of proven and probable invasive mold infection (IMI)
- Cumulative incidence of possible invasive mold infection (IMI)
- Cumulative incidence of probable and proven Invasive Fungal Infections (IFI)
- (and 6 more...)
|
320 |
All |
18 Years and older (Adult, Older Adult) |
NCT03828773 |
2018-01671 |
PTX3AML |
February 11, 2019 |
July 31, 2022 |
July 31, 2022 |
February 4, 2019 |
February 15, 2019 |
|
- University Hospital of Lausanne / Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Vaud, Switzerland - University Hospital of Geneva (HUG)
Geneva, Switzerland
|
|
| 100 |
NCT03054155 |
Recruiting |
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser |
|
- Device: Alexandrite Laser
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03054155 |
120116M1F |
|
May 11, 2017 |
October 31, 2019 |
October 31, 2019 |
February 15, 2017 |
October 5, 2018 |
|
- Wayne State University Physician Group Dermatology
Dearborn, Michigan, United States
|
|
Create an RSS feed from your search for:
Download the search results for: